BOSTON and WATERTOWN, Mass. - Standard BioTools Inc. (NASDAQ:LAB) and Treeline Biosciences announced Monday they have entered into a definitive merger agreement to combine in an all-stock transaction expected to close in the second half of 2026.
The combined company will operate under the name Treeline Biosciences and trade on Nasdaq under the ticker symbol TRLN. Upon completion, pre-merger Standard BioTools stockholders are expected to own approximately 16% of the combined company, while pre-merger Treeline stockholders will own approximately 84%, according to a press release statement.
The transaction values Standard BioTools at net cash delivered at closing plus $10 million, estimated at $460 million. This valuation aligns closely with LAB’s current market cap of approximately $449 million, though the stock trades at $1.15, down from $1.27 at the previous close. According to InvestingPro analysis, the company appears undervalued at current levels based on its Fair Value assessment. Standard BioTools will add approximately $450 million in net cash to the combined company’s balance sheet. At closing, the combined company is expected to have more than $900 million in pro-forma cash, which is expected to fund operations into 2029. InvestingPro Tips highlight that Standard BioTools holds more cash than debt on its balance sheet, though the company has been quickly burning through cash—making this merger’s capital infusion strategically important. Investors can access 7 additional ProTips and a comprehensive Pro Research Report on LAB for deeper analysis.
Treeline, founded in 2021, has three programs in Phase 1 clinical trials with multiple anticipated clinical data readouts beginning in 2027. A fourth program is expected to enter Phase 1 in 2026. The company’s pipeline includes small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates addressing molecular targets in oncology, neurology and immunology.
Josh Bilenker, co-founder and Chief Executive Officer of Treeline, will lead the combined company. Bilenker previously founded Loxo Oncology, which was acquired by Eli Lilly for $8 billion. Jeff Engelman will serve as Chief Scientific Officer and Spencer Smith as Chief Financial Officer.
Standard BioTools is exploring options, including divestitures, to maximize the value of its Mass Cytometry and Microfluidics businesses, which Treeline does not intend to operate. Pre-combination Standard BioTools stockholders will receive one contingent value right per share representing the right to receive certain payments based on net proceeds from legacy assets.
The transaction requires Standard BioTools stockholder approval and regulatory approvals. Treeline stockholders have already approved the transaction. Treeline previously raised approximately $1.2 billion from life sciences investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for LAB plus thousands of other stocks and find your next hidden gem with massive upside.